Biogen Inc. (BIIB) Earnings Call Transcripts
Biogen Inc.'s Latest Earnings Call - September 14, 2026
In Biogen's Q3 2026 earnings call, management highlighted a strategic shift towards immunology and diversification of its pipeline, which could drive future revenue growth. The company reported revenues of $2.1 billion, slightly below the $2.2 billion consensus estimate, resulting in a net loss of $0.15 per share, missing expectations by $0.10. Management maintained its full-year revenue guidance of $8.5 billion, signaling confidence in upcoming product launches and pipeline advancements.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $2.1B (miss) |
| EPS | -$0.15 (miss) |
| Full-Year Revenue Guidance | $8.5B (inline) |
| Phase III Trials | 10 (positive) |
| LEQEMBI Market Share | null (positive) |
| Lupus Market Opportunity | $8B (positive) |
Guidance from management
Management maintained full-year revenue guidance of $8.5 billion, indicating confidence in upcoming product launches and pipeline advancements.
What management said
Yes, it is because you're getting a number of assets, particularly immunology, where you've got already where the underlying disease biology is pretty well defined. So they have -- there is some areas of this that are highly competitive. At the same time, we have China coming in. And so the supply, if you like, of early-stage assets has expanded significantly.
Well, Medicare makes all those decisions effective 1st to January. So that won't slip. What we don't know is you have -- there will be some plans that will reimburse subcutaneous for all indications. We got approval in July, so that's theoretically in advance of the announcement in the kind of late fall time frame. So we'll have to wait and see which plans reimburse for both indications or at all. So -- but I think w...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape in Alzheimer's treatment, particularly with Roche's new approaches. Additionally, there were questions about the potential success of the lupus pipeline given the historical challenges in this area.
Main topics on the call
- Strategic Shift to Immunology — Management emphasized a significant pivot towards immunology, stating, "we're building out a commercial team that's not only seeing neurologists, but also nephrologists, transplant nephrologists, rheumatologists..." This...
- LEQEMBI Market Dynamics — Management noted that while there is a large unmet need in Alzheimer's, uptake for LEQEMBI has been slower than anticipated due to complexities in treatment pathways. They are working to simplify these pathways, stating,...
- Upcoming Product Launches — Biogen is preparing for multiple product launches, with management indicating, "we've got 10 Phase III clinical trials that will start to read out as soon as next quarter..." This could significantly impact future revenu...
- Acquisition of Apellis — The acquisition of Apellis was framed as a strategic move to enhance Biogen's immunology portfolio, with management stating, "we have the potential to really have an inflection in our revenue growth."
Read the full Biogen Inc. transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Biogen Inc.
Biogen Inc. (BIIB) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 98 calls on record spanning January 13, 2020 to September 14, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 98 Biogen Inc. earnings call transcripts on record, spanning January 13, 2020 to September 14, 2026. Based on this history, Biogen Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BIIB
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 98
- First call
- January 13, 2020
- Most recent
- September 14, 2026
- Reporting cadence
- quarterly